Expert Review of Vaccines最新文献_第3页

Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China. 一种减毒水痘活疫苗在13 - 55岁健康受试者中的免疫原性和安全性：一项在中国开展的双盲、随机、主动对照iii期临床试验

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-02-07 DOI: 10.1080/14760584.2025.2457463

Yang Zhang, Shiyuan Wang, Guifan Li, Jinhui Shi, Xianyun Chang, Hao Zhang, Fengcai Zhu, Jingxin Li, Hongxing Pan, Jinfang Sun

{"title":"Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China.","authors":"Yang Zhang, Shiyuan Wang, Guifan Li, Jinhui Shi, Xianyun Chang, Hao Zhang, Fengcai Zhu, Jingxin Li, Hongxing Pan, Jinfang Sun","doi":"10.1080/14760584.2025.2457463","DOIUrl":"10.1080/14760584.2025.2457463","url":null,"abstract":"Background: Adolescents and adults who contract chickenpox are at a higher risk of severe complications. Vaccination with the varicella vaccine (VarV) effectively prevents chickenpox.Research design and methods: In this phase III, single-center, randomized, double-blind, active-controlled trial, 1,200 healthy participants were randomly assigned in a 1:1 ratio to receive two doses of either the test vaccine or the active control vaccine. Varicella-zoster virus (VZV) antibody was detected before vaccination and 42 days after the two doses of vaccination.Results: The lower limits of the 95% CI for the differences in seroconversion rates and geometric mean titer (GMT) ratios between the two groups were greater than their respective pre-set non-inferiority margins. The overall incidence of Adverse events (AEs) and adverse reactions (ARs) in the test group was significantly lower than those in the control group. Additionally, the incidence rates of swelling and fatigue were lower in the test group compared to the control group after vaccination.Conclusions: The test freeze-dried live attenuated VarV demonstrated good immunogenicity and higher safety compared to the active control vaccine in healthy participants aged 13-55 years.Clinical trials registration: www.clinicaltrials.gov identifier: NCT06592456.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"157-164"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Virus-like particles: a versatile and effective vaccine platform. 病毒样颗粒：一个多功能和有效的疫苗平台。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-22 DOI: 10.1080/14760584.2025.2508517

Martin F Bachmann, Pierre van Damme, Florian Lienert, Tino F Schwarz

{"title":"Virus-like particles: a versatile and effective vaccine platform.","authors":"Martin F Bachmann, Pierre van Damme, Florian Lienert, Tino F Schwarz","doi":"10.1080/14760584.2025.2508517","DOIUrl":"10.1080/14760584.2025.2508517","url":null,"abstract":"Introduction: Traditional live-attenuated or inactivated vaccines have limitations, including risks associated with uncontrolled replication, reduced immunogenicity, or production complexities. To address these issues, alternative platforms such as virus-like particles (VLPs) have been developed.Areas covered: VLPs are self-assembling structures composed of viral proteins that mimic native viruses but are noninfectious. This review provides an overview of their structure, design and manufacture that make them an attractive platform for vaccine development. We then discuss the clinical development of some recently approved VLP vaccines and those widely used in immunization programs, summarizing the clinical trial data that underpins their efficacy and safety profiles. Additionally, we explore VLP vaccines in late-stage clinical development for respiratory syncytial virus and human metapneumovirus.Expert opinion: VLPs are a versatile and promising platform for vaccine development. Their ability to mimic native viruses while eliminating the risks associated with live vaccines positions them as an attractive platform for vaccine design. Currently approved VLP vaccines demonstrate that they can provide effective protection against a wide range of diseases. Advances in VLP design and production are likely to lead to highly effective vaccines, significantly contributing to global immunization efforts.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"444-456"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Strengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States. 评估美国成人疫苗接种覆盖率的非调查数据来源的优势和局限性。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-27 DOI: 10.1080/14760584.2025.2483719

Matthew F Daley, Kamonthip J Homdayjanakul, Laura P Hurley, Peng-Jun Lu, Yuping Tsai, Carla L Black, Suchita Patel, James A Singleton, Lori A Crane

{"title":"Strengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States.","authors":"Matthew F Daley, Kamonthip J Homdayjanakul, Laura P Hurley, Peng-Jun Lu, Yuping Tsai, Carla L Black, Suchita Patel, James A Singleton, Lori A Crane","doi":"10.1080/14760584.2025.2483719","DOIUrl":"10.1080/14760584.2025.2483719","url":null,"abstract":"Introduction: Non-survey-based data sources (e.g. electronic health records, administrative claims) have been used to estimate vaccination coverage among US adults. However, these data sources were not collected for research or surveillance purposes and may have substantial limitations. The objectives of this narrative review were to: 1) identify published studies that used non-survey-based data sources to estimate adult vaccination coverage for one or more routinely recommended vaccines; and 2) summarize the strengths and limitations of these data sources for coverage assessments.Areas covered: Thirty-four publications derived from 9 data sources were reviewed: 16 publications were in a general population (i.e. defined by age), 12 were among pregnant women, and 6 were among individuals with chronic health conditions. While several data sources used continuous health insurance enrollment to define the study population, doing so limited generalizability to stably insured populations. Methods for obtaining race and ethnicity data were complex and potentially subject to bias. None of the reviewed studies presented any formal assessment of vaccine data validity.Expert opinion: While multiple non-survey-based data sources have been used to assess adult vaccination coverage in the United States, important limitations exist, including related to generalizability, data validity, and risk of bias.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"230-241"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis. omicron XBB 1.5适应COVID-19疫苗的比较有效性：系统文献综述和网络荟萃分析

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-05-19 DOI: 10.1080/14760584.2025.2505754

Kyle Fahrbach, Allie Cichewicz, Haitao Chu, Manuela Di Fusco, Heather Burnett, Hannah R Volkman, Morodoluwa Akin-Fajiye, Carlos Fernando Mendoza, Joseph C Cappelleri

{"title":"Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis.","authors":"Kyle Fahrbach, Allie Cichewicz, Haitao Chu, Manuela Di Fusco, Heather Burnett, Hannah R Volkman, Morodoluwa Akin-Fajiye, Carlos Fernando Mendoza, Joseph C Cappelleri","doi":"10.1080/14760584.2025.2505754","DOIUrl":"10.1080/14760584.2025.2505754","url":null,"abstract":"Introduction: Comparative effectiveness data of COVID-19 vaccines remain limited. We conducted a systematic review and network meta-analysis (NMA) feasibility assessment of effectiveness studies of Omicron-adapted COVID-19 vaccines.Research design and methods: Searches in MEDLINE and Embase up to February 2025 identified studies comparing the effectiveness of Omicron-adapted COVID-19 vaccines, either directly or against no recent vaccine. Two investigators independently selected articles reporting adjusted vaccine effectiveness (VE). A feasibility assessment determined the appropriateness of a common comparator and evaluated effect modifiers (EMs). Data extraction and risk-of-bias assessment were performed by one investigator and validated by a second investigator. Bayesian NMAs using random-effects models were performed for base-case analyses, data permitting.Results: The review identified 25 studies for Omicron-adapted COVID-19 vaccines: 16 for XBB formulations, eight of which were included in NMAs, all for mRNA formulations, representing 29.9 million participants. BNT162b2 had the largest evidence base. Comparisons between XBB.1.5-adapted BNT162b2 (Comirnaty) and mRNA-1273 (Spikevax) found that both vaccines are effective and comparable against XBB-related hospitalizations, infections, and medically attended visits in adults Among elderly, the estimated effectiveness against XBB-related hospitalizations favored BNT162b2.Conclusions: Findings of this NMA of observational studies support the effectiveness of XBB.1.5-adapted mRNA vaccines. Limitations included assumptions on EMs and sparse evidence networks.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"416-432"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in transmission-blocking vaccines against Plasmodium falciparum and Plasmodium vivax. 恶性疟原虫和间日疟原虫传播阻断疫苗的研究进展。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-06-18 DOI: 10.1080/14760584.2025.2517720

Mayumi Tachibana, Eizo Takashima, Motomi Torii, Yimin Wu, Jetsumon Sattabongkot, Takafumi Tsuboi

引用次数: 0

A benefit-cost analysis quantifying the broader socioeconomic value of adult respiratory vaccination programs in Japan. 效益-成本分析量化了日本成人呼吸道疫苗接种计划的更广泛的社会经济价值。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-22 DOI: 10.1080/14760584.2025.2536092

Claud Theakston, Matthew Napier, Simon Brassel, Kazumasa Kamei, Shuhei Ito, Jeffrey Vietri, Diana Mendes, Jingyan Yang, Tianyan Hu, Lotte Steuten

{"title":"A benefit-cost analysis quantifying the broader socioeconomic value of adult respiratory vaccination programs in Japan.","authors":"Claud Theakston, Matthew Napier, Simon Brassel, Kazumasa Kamei, Shuhei Ito, Jeffrey Vietri, Diana Mendes, Jingyan Yang, Tianyan Hu, Lotte Steuten","doi":"10.1080/14760584.2025.2536092","DOIUrl":"10.1080/14760584.2025.2536092","url":null,"abstract":"Background: Respiratory infections like pneumococcal disease (PD), respiratory syncytial virus (RSV), influenza (Flu), and COVID-19 significantly impact Japan's aging population, imposing substantial health and economic burdens. Effective vaccines exist, yet uptake remains limited due to funding constraints and vaccine hesitancy. This study assessed the societal return on investment in adult respiratory vaccination programs to support informed policy decisions.Research design & methods: We conducted a benefit-cost analysis using static cohort models and life tables to estimate benefit-cost ratios (BCRs) and societal net benefits (NBs), monetizing health impacts through the value of statistical life and cost-of-illness methods. Costs comprised vaccination program expenses. Scenario and sensitivity analyses explore coverage scenarios and parameter assumptions.Results: Adult vaccination programs generated BCRs around 18:1 within 5 years and 20:1 over a lifetime. Lifetime NBs exceeded ¥113 trillion, preventing nearly three million hospitalizations and freeing millions of hospital bed-days, alongside avoiding over ¥100 billion in productivity losses. Expanding vaccine coverage significantly increased the NBs by > 30%, whereas reduced COVID-19 vaccine uptake notably diminished returns.Conclusion: Japan's adult respiratory vaccination programs generate substantial socioeconomic returns, strengthening public health, healthcare resilience, and workforce productivity. Increasing uptake across the population can generate significantly higher NBs. Realizing these benefits requires addressing vaccine uptake barriers and enhancing public investment.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"633-643"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunization information systems' implementation and characteristics across the world: a systematic review of the literature. 免疫信息系统在世界各地的实施和特点：文献的系统回顾。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-29 DOI: 10.1080/14760584.2025.2510338

Giacomo Pietro Vigezzi, Elena Maggioni, Laura Clavario, Lorenzo Clerico Mosina, Eleonora Raso, Corina Marjin, Andrea Parrini, Matteo Carbone, Simone Fugazza, Alberto Marchisio, Manuela Martella, Giansanto Mosconi, Giuseppina Lo Moro, Fabrizio Bert, Corrado De Vito, Roberta Siliquini, Anna Odone

{"title":"Immunization information systems' implementation and characteristics across the world: a systematic review of the literature.","authors":"Giacomo Pietro Vigezzi, Elena Maggioni, Laura Clavario, Lorenzo Clerico Mosina, Eleonora Raso, Corina Marjin, Andrea Parrini, Matteo Carbone, Simone Fugazza, Alberto Marchisio, Manuela Martella, Giansanto Mosconi, Giuseppina Lo Moro, Fabrizio Bert, Corrado De Vito, Roberta Siliquini, Anna Odone","doi":"10.1080/14760584.2025.2510338","DOIUrl":"10.1080/14760584.2025.2510338","url":null,"abstract":"Introduction: Immunization Information Systems (IISs) are essential public health tools, supporting the management and analysis of vaccination data to aid clinical and strategic decision-making.Methods: Following PRISMA guidelines, this systematic review investigated global state and operational characteristics of IISs. A comprehensive search across multiple databases up to 6th of June 2023, identified 2,612 articles, with 238 included.Results: A significant increase in IIS research was observed in recent years, with a strong preference (84.5%) for electronic immunization registers (EIRs). Notably, 36% of IISs operate at the national level, and 47.7% meet the U.S. CDC definition, 17.0% are interoperable with personal health records, and 11.7% provide direct access to vaccination data for vaccinees or their guardians. Other key features include automated reminder systems for recipients and providers (12.1%), near real-time or real-time data entry (11.0%), the inclusion of demographic and socioeconomic data (16.7%), and the capacity to document vaccine refusal or hesitancy (10.2%).Conclusions: IISs contribute to improving population-level surveillance of vaccine-preventable diseases. Persistent limitations related to data standardization, interoperability, and cost-effectiveness evaluation must be addressed. Strengthening these aspects is crucial to fully harness the potential of IISs in various healthcare settings, where enhanced vaccination tracking and targeting are most urgently needed.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"668-702"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of CoronaVac primary series with and without booster against hospitalized COVID-19 during the Omicron-predominant epidemic wave in the Philippines: a test-negative case-control study. 在菲律宾以omicron为主的流行波期间，CoronaVac一级系列有和没有加强剂对住院的COVID-19的有效性：一项检测阴性的病例对照研究。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-31 DOI: 10.1080/14760584.2025.2539889

Kristal An Agrupis, Michelle Ylade, Yang Yang Qi, Maria Vinna Crisostomo, Jedas Veronica Daag, Gianne Lariz Magsakay, Jude Raphael Lo, Kiarah Louise Florendo, March Helena Jane Lopez, Jayne Marie Enriquez, Irish Lobitaña, Gretchen Bonita Ranada, Regina Alfonso, Mitzi Marie Chua, Mitzie Lou Osabel, Mary Ann Igoy-Bacay, Carren Anne Bocaling, Lorenz Von Seidlein, Xuanyi Wang, Jacqueline Deen

{"title":"Effectiveness of CoronaVac primary series with and without booster against hospitalized COVID-19 during the Omicron-predominant epidemic wave in the Philippines: a test-negative case-control study.","authors":"Kristal An Agrupis, Michelle Ylade, Yang Yang Qi, Maria Vinna Crisostomo, Jedas Veronica Daag, Gianne Lariz Magsakay, Jude Raphael Lo, Kiarah Louise Florendo, March Helena Jane Lopez, Jayne Marie Enriquez, Irish Lobitaña, Gretchen Bonita Ranada, Regina Alfonso, Mitzi Marie Chua, Mitzie Lou Osabel, Mary Ann Igoy-Bacay, Carren Anne Bocaling, Lorenz Von Seidlein, Xuanyi Wang, Jacqueline Deen","doi":"10.1080/14760584.2025.2539889","DOIUrl":"10.1080/14760584.2025.2539889","url":null,"abstract":"Background: CoronaVac (Sinovac) was initially effective against symptomatic COVID-19 and severe outcomes, but its performance against the immune-evasive Omicron variant remains uncertain. This study evaluated the effectiveness of CoronaVac against hospitalized COVID-19 among Filipino adults during the Omicron-dominant wave.Research design and methods: We conducted a test-negative case-control study from November 2022 to November 2023 in three tertiary government hospitals in the Philippines. Adults hospitalized with acute respiratory illness (ARI) were enrolled. Cases tested positive for SARS-CoV-2 by RT-PCR; controls tested negative. Vaccination status was confirmed via vaccination cards or the national registry. Conditional logistic regression estimated vaccine effectiveness (VE). Genomic sequencing identified circulating variants.Results: Among 2,365 participants, 165 (7.0%) were COVID-19 positive. In an age-matched analysis (104 cases, 408 controls), two CoronaVac doses provided 61.3% protection (95% CI: 5.3-84.2%) against critical illness. A heterologous booster conferred 65.9% protection against severe disease, 90.1% against critical illness, and 60.5% against death. Sequencing of 23/46 samples confirmed Omicron XBB-like variants.Conclusion: Two doses of CoronaVac offered moderate protection against severe COVID-19. Heterologous boosters significantly improved protection, especially against critical illness and death, supporting ongoing booster campaigns after inactivated vaccine priming.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"738-749"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018-2024: a database study. 2018-2024 年美国药房和医疗机构中青少年和成人疫苗接种趋势：一项数据库研究。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-22 DOI: 10.1080/14760584.2024.2441255

Yi Zheng, Dong Wang, Ya-Ting Chen, Kunal Saxena, Goran Bencina, Amanda L Eiden

{"title":"Trends in adolescent and adult vaccination in pharmacy and medical settings in the United States, 2018-2024: a database study.","authors":"Yi Zheng, Dong Wang, Ya-Ting Chen, Kunal Saxena, Goran Bencina, Amanda L Eiden","doi":"10.1080/14760584.2024.2441255","DOIUrl":"10.1080/14760584.2024.2441255","url":null,"abstract":"Background: Pharmacies can increase access to vaccines. This study aimed to describe trends in the proportion of adolescent and adult vaccinations administered in pharmacies in the United States from 2018 to 2024.Research design and methods: This was a retrospective cross-sectional analysis of medical and pharmacy claims from commercial health insurance enrollees. We recorded vaccinations received by enrollees ≥9 years of age from 2018 to 2023 (routine vaccines) or 2024 (seasonal vaccines). We calculated the annual proportion of vaccinations occurring in pharmacies and the accumulated percent change in vaccination rate during each year from 2020 onward compared to 2018-2019.Results: The proportion of routine vaccinations occurring in pharmacies was higher among adults than among adolescents. For most routine vaccines, this proportion increased during the study period. The lowest proportion was observed for adolescent human papillomavirus vaccination in 2018 (0.2%), and the highest for herpes zoster vaccination among adults ≥65 years of age in 2023 (88.6%). For all age groups, pharmacy-based vaccination was more common for seasonal influenza and SARS-CoV-2 vaccines than for all routine vaccines except herpes zoster.Conclusions: Pharmacy-based vaccination is increasingly common in the United States, particularly among adults and for seasonal vaccines, and can help increase the overall level of vaccine uptake.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"53-66"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of non-pharmacological interventions on nasopharyngeal Staphylococcus aureus, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae carriage and the change of pneumococcal vaccination in healthy children under 5 years old in Beijing, China. 非药物干预对北京地区5岁以下健康儿童鼻咽金黄色葡萄球菌、肺炎链球菌、卡他莫拉菌、流感嗜血杆菌携带及肺炎球菌疫苗接种变化的影响

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-13 DOI: 10.1080/14760584.2025.2476521

Qianqian Du, Zhaoqiu Liu, Wei Shi, Xijie Liu, Qinghong Meng, Dongyi Zheng, Kaihu Yao

{"title":"The impact of non-pharmacological interventions on nasopharyngeal Staphylococcus aureus, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae carriage and the change of pneumococcal vaccination in healthy children under 5 years old in Beijing, China.","authors":"Qianqian Du, Zhaoqiu Liu, Wei Shi, Xijie Liu, Qinghong Meng, Dongyi Zheng, Kaihu Yao","doi":"10.1080/14760584.2025.2476521","DOIUrl":"10.1080/14760584.2025.2476521","url":null,"abstract":"Background: We analyzed the impact of non-pharmacological interventions (NPIs) and PCV13 inoculation on nasopharyngeal (NP) carriage of Staphylococcus aureus (Sa), Streptococcus pneumoniae (Sp), Moraxella catarrhalis (Mc), and Haemophilus influenzae (Hi) in healthy children under 5-years-old in Beijing, China.Research design and methods: NP swabs were taken from healthy children seeking routine well-child care at the pediatric preventive health clinic. NP swabs were frozen in Tryptic Soy Broth (TSB) medium and stored at -80°C, and bacterial was detected by culture.Results: From December 2019 to November 2021, 1939 children were enrolled, among whom 278 (14.3%) were found to carry Sa isolates, 115 (5.9%) Sp, 39 (2.0%) Mc, and 6 (0.3%) Hi. The carriage of Sa was highest in infants under 6 months, negatively correlated with Sp and Mc. The Sa carriage rate in infants below 6 months of age rose from 26.7% in pre-NPIs to 32.7% in post-NPIs early. The 13-valent pneumococcal conjugate vaccine (PCV13) uptake rose from 42.3% in December 2019 to 62.3% by October 2021.Conclusions: The broad application of NPIs caused a decline in Sp and Mc carriage among children under 5-years-old, accompanied by an elevation in the Sa carriage rate among infants.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"206-211"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0